Related Experiment Video
Updated: Jun 20, 2026
09:34
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
SRD5A2 V89L polymorphism and prostate cancer risk: a meta-analysis
Chunyang Wang1, Weiyang Tao, Qiyin Chen
1Tianjin Institute of Urological Surgery, Tianjin Key Laboratory of Urology, Tianjin Medical University, Tianjin, China.
The Prostate
|September 18, 2009
Summary
The steroid 5-alpha reductase type II gene polymorphism (SRD5A2 V89L) may slightly increase prostate cancer (PCa) risk in European men and those under 65. Further research is needed to confirm these findings on PCa susceptibility.
Area of Science:
- Genetics and Genomics
- Cancer Epidemiology
- Molecular Biology
Background:
- Prostate cancer (PCa) susceptibility is influenced by genetic factors.
- The steroid 5-alpha reductase type II gene polymorphism at codon 89 (SRD5A2 V89L) has been investigated for its association with PCa risk.
- Previous studies have yielded inconsistent results regarding the SRD5A2 V89L polymorphism and PCa susceptibility.
Purpose of the Study:
- To conduct a meta-analysis to precisely estimate the relationship between the SRD5A2 V89L polymorphism and prostate cancer risk.
- To increase statistical power by pooling data from multiple case-control studies.
Main Methods:
- A comprehensive literature search was performed to identify relevant case-control studies.
- Odds ratios (OR) and 95% confidence intervals (CI) were calculated to assess effect sizes.
- Meta-analysis techniques were employed to synthesize findings across studies.
Main Results:
- Twenty-five eligible reports comprising 8,615 cases and 9,089 controls were analyzed.
- Overall, no significant association was found between SRD5A2 V89L polymorphism and PCa risk across all genetic models.
- Subgroup analyses indicated a potential increased PCa risk in Europeans (dominant and L allele models) and men aged <=65 (co-dominant and recessive models).
- No significant associations were observed in Asian or African populations.
Conclusions:
- The SRD5A2 V89L polymorphism may play a low-penetrant role in prostate cancer risk, particularly among European populations and individuals younger than 65 years.
- These findings suggest a nuanced genetic contribution to PCa susceptibility.
- Further well-designed studies are recommended to validate these observations and elucidate the underlying mechanisms.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
02:38The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...